AstraZeneca’s $50 billion investment will expand US drug manufacturing and R&D, boosting innovation and creating new job opportunities in key locations.
The EU spent €381.4 billion on R&D in 2023, up 6.7% from 2022, maintaining an R&D intensity of 2.2%, with the business sector leading investment at 66% of total funding.
